IMCR — Immunocore Holdings plc
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1671927 ·
Last close
$36.61
Market Cap
$1.89B
52W High
$37.44
52W Low
$27.59
ADV30
480,479
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 115,927,000 | 114,839,000 | -2,996,000 | -808,000 | 1,119,422,000 | 484,920,000 | 699,624,000 |
| Mar 2026 | 106,677,000 | 106,243,000 | 7,280,000 | 12,971,000 | 1,072,095,000 | 452,675,000 | 678,422,000 |
| Dec 2025 | 104,478,000 | 101,775,000 | -19,691,000 | -30,060,000 | 1,067,269,000 | 467,709,000 | 686,236,000 |
| Sep 2025 | 103,693,000 | 103,180,000 | -7,171,000 | -177,000 | 1,102,500,000 | 498,413,000 | 705,936,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-34,958,000
Investing CF
$7,805,000
Financing CF
$23,291,000
CapEx
$-6,195,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.37
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-819,112,000
Inventory
$7,791,000
Receivables
$95,350,000
ST Investments
$395,291,000
EBIT TTM
$9,969,000
Pretax Income TTM
$-2,732,000
Interest Exp TTM
$12,701,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$430,775,008
EBITDA
$756,000
Free Cash Flow
$35,592,124
Enterprise Value
$1,440,112,384
Total Cash
$880,211,008
Total Debt
$434,959,008
Shares Out
51,498,617
Trailing EPS
$-0.36
Book Value
$8.15
ROE
-4.5%
ROA
-0.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 400,016,000 | -45,353,000 | -35,514,000 | 1,067,269,000 | 686,236,000 | — | -10,712,000 |
| Dec 2024 | 310,202,000 | -70,461,000 | -51,087,000 | 1,009,506,000 | 648,790,000 | — | 26,061,000 |
| Dec 2023 | 249,428,000 | -59,649,000 | -55,287,000 | 597,001,000 | 228,158,000 | — | 2,940,000 |
| Dec 2022 | 174,361,000 | -51,708,000 | -52,543,000 | 526,762,000 | 187,859,000 | — | -49,209,000 |
TTM Snapshot
Revenues TTM
$145,098,000
NetIncome TTM
$9,642,000
OpCashFlow TTM
$0
Assets (Latest)
$1,009,506,000
Forward EPS
$-0.76
Max Pain — expiry 2026-10-16
max pain strike: $30.00 · spot: $37.09 · call oi: 6,683 · put oi: 5,300Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALVO | Alvotech | $1.87B | $5.25 | — |
| TSHA | Taysha Gene Therapies, Inc. | $1.95B | $5.97 | — |
| RXRX | RECURSION PHARMACEUTICALS, INC. | $1.74B | $3.25 | — |
| VIR | Vir Biotechnology, Inc. | $1.68B | $9.91 | — |
| ADMA | ADMA BIOLOGICS, INC. | $2.14B | $9.55 | — |
News headlines (Yahoo Finance, 1h cache)
Will Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026?
2026-08-25 15:07 · Yahoo
IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss
2026-08-10 15:39 · Yahoo
How Strong H1 Profits and Kimtrak Survival Data At Immunocore (IMCR) Have Changed Its Investment Story
2026-08-07 08:15 · Yahoo
Immunocore Q2 Earnings Call Highlights
2026-08-06 19:04 · Yahoo
Immunocore Holdings PLC (IMCR) (Q2 2026) Earnings Call Highlights: Kimtrak Growth and Pipeline ...
2026-08-06 19:02 · Yahoo
Immunocore Holdings PLC (IMCR) (Q2 2026) Earnings Call Highlights: Strong Kimtrak Growth and ...
2026-08-06 17:06 · Yahoo
Immunocore reports second quarter financial results and provides a business update
2026-08-06 11:00 · Yahoo
Immunocore to report second quarter 2026 financial results and host call on August 6, 2026
2026-07-30 11:00 · Yahoo
How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak
2026-07-27 15:54 · Yahoo
Is Immunocore Stock Attractive After Kimmtrak's Strong Sales Growth?
2026-07-27 15:53 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.